Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart A Montgomery

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
International Clinical Psychopharmacology|October 29, 2013
Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levelsStuart A Montgomery, A Carlo Altamura, Heikki Katila, et al.
The Journal of Clinical Psychiatry|April 11, 2009
Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled studyAndrew J Cutler, Stuart A Montgomery, David Feifel, et al.
International Clinical Psychopharmacology|October 2, 2012
Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo controlSiegfried Kasper, Emmanuelle Corruble, Anthony Hale, et al.
International Clinical Psychopharmacology|September 26, 2009
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorderStuart A Montgomery, Maurizio Fava, Sudharshan K Padmanabhan, et al.
The Journal of Clinical Psychiatry|December 29, 2007
Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trialsGeorge I Papakostas, Stuart A Montgomery, Michael E Thase, et al.
The Journal of Clinical Psychiatry|April 6, 2016
Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorderSuresh Durgam, Willie Earley, Hua Guo, et al.
Journal of Affective Disorders|July 2, 2013
Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorderMichael Bauer, Liliana Dell'osso, Siegfried Kasper, et al.
International Clinical Psychopharmacology|August 8, 2012
Evaluation of depressive symptoms in patients with coronary artery disease using the Montgomery Åsberg Depression Rating ScaleAdomas Bunevicius, Margarita Staniute, Julija Brozaitiene, et al.
The International Journal of Neuropsychopharmacology|November 2, 2005
Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorderStuart A Montgomery, John P Feighner, Lev Sverdlov, et al.
International Clinical Psychopharmacology|June 12, 2008
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorderDaniel Z Lieberman, Stuart A Montgomery, Karen A Tourian, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
International Clinical Psychopharmacology|October 29, 2013
Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levelsStuart A Montgomery, A Carlo Altamura, Heikki Katila, et al.
The Journal of Clinical Psychiatry|April 11, 2009
Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled studyAndrew J Cutler, Stuart A Montgomery, David Feifel, et al.
International Clinical Psychopharmacology|October 2, 2012
Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo controlSiegfried Kasper, Emmanuelle Corruble, Anthony Hale, et al.
International Clinical Psychopharmacology|September 26, 2009
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorderStuart A Montgomery, Maurizio Fava, Sudharshan K Padmanabhan, et al.
The Journal of Clinical Psychiatry|December 29, 2007
Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trialsGeorge I Papakostas, Stuart A Montgomery, Michael E Thase, et al.
The Journal of Clinical Psychiatry|April 6, 2016
Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorderSuresh Durgam, Willie Earley, Hua Guo, et al.
Journal of Affective Disorders|July 2, 2013
Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorderMichael Bauer, Liliana Dell'osso, Siegfried Kasper, et al.
International Clinical Psychopharmacology|August 8, 2012
Evaluation of depressive symptoms in patients with coronary artery disease using the Montgomery Åsberg Depression Rating ScaleAdomas Bunevicius, Margarita Staniute, Julija Brozaitiene, et al.
The International Journal of Neuropsychopharmacology|November 2, 2005
Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorderStuart A Montgomery, John P Feighner, Lev Sverdlov, et al.
International Clinical Psychopharmacology|June 12, 2008
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorderDaniel Z Lieberman, Stuart A Montgomery, Karen A Tourian, et al.
Pageof 5